Foresite Capital Management I’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-19,100
| Closed | -$3.29M | – | 4 |
|
|
2021
Q3 | $3.29M | Hold |
19,100
| – | – | 2.57% | 3 |
|
|
2021
Q2 | $2.4M | Hold |
19,100
| – | – | 1.45% | 4 |
|
|
2021
Q1 | $2.59M | Hold |
19,100
| – | – | 1.31% | 3 |
|
|
2020
Q4 | $2.44M | Hold |
19,100
| – | – | 1.29% | 4 |
|
|
2020
Q3 | $2.15M | Buy |
19,100
+11,100
| +139% | +$1.11M | 0.61% | 4 |
|
|
2020
Q2 | $762K | Hold |
8,000
| – | – | 0.24% | 3 |
|
|
2020
Q1 | $719K | Hold |
8,000
| – | – | 0.2% | 2 |
|
|
2019
Q4 | $424K | Buy |
+8,000
| New | +$365K | 0.08% | 2 |
|
|
2015
Q3 | $4.04M | Hold |
162,070
| – | – | 43.03% | 1 |
|
|
2015
Q2 | $5.13M | Buy |
162,070
+68,289
| +73% | +$2.2M | 33.85% | 2 |
|
|
2015
Q1 | $3.57M | Buy |
93,781
+38,014
| +68% | +$1.51M | 16.42% | 3 |
|
|
2014
Q4 | $2.17M | Hold |
55,767
| – | – | 3.2% | 6 |
|
|
2014
Q3 | $1.69M | Hold |
55,767
| – | – | 1.61% | 8 |
|
|
2014
Q2 | $1.89M | Buy |
55,767
+34,875
| +167% | +$1.17M | 1.59% | 8 |
|
|
2014
Q1 | $721K | Sell |
20,892
-45,108
| -68% | -$2.04M | 0.51% | 11 |
|
|
2013
Q4 | $2.61M | Buy |
+66,000
| New | +$1.59M | 2.54% | 7 |
|
Foresite Capital Management I's XLRN Position: Q4 2021 in Review
Foresite Capital Management I sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 19,100 shares — an estimated $3.29M sold.
Foresite Capital Management I first reported a position in XLRN in Q4 2013 and held it in 16 quarters. The position peaked at $5.13M in Q2 2015. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Foresite Capital Management I reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Foresite Capital Management I sold 19,100 Acceleron Pharma shares in Q4 2021, an estimated $3.29M.
- Foresite Capital Management I first reported a position in Acceleron Pharma in Q4 2013 and held it in 16 quarters.
- Foresite Capital Management I's Acceleron Pharma position peaked at $5.13M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Foresite Capital Management I's 13F filing for Q4 2021, filed 11 Feb 2022.